Background
==========

The human multidrug resistance 1 (*MDR1* or *ABCB1*) gene encodes a 170-kDa membrane transport protein called P-glycoprotein. For minimizing the exposure of potential toxic compounds to the cellular homeostasis, P-glycoprotein is expressed primarily in regions that act as epithelial barriers or perform excretory functions, including blood-tissue barrier, the gastrointestinal tract, liver and kidney. Therefore, P-glycoprotein can play the role of sweeper by extruding several exogenous and endogenous substances, using ATP-dependent efflux pump \[[@B1]-[@B4]\]. The alteration of the cellular defense mechanism mediated by P-gp has been speculated to be closely associated with the development of various cancers including hepatocarcinoma, colorectal carcinoma, acute lymphoblastic leukemia and gall bladder tumors \[[@B5]-[@B8]\]. These suggest that *MDR1* may play an important role in the elimination of carcinogens, and the mutation of *MDR1* may lead to human malignancies \[[@B5]\]. Several studies try to prove the causal function of P-gp in tumorigenesis by animal experiments. One study by Mochida Y et al. suggested that the absence of the P-gp role suppressed the development of intestinal neoplasia in Apc (Min/+) mice, and a P-gp inhibitor was found to suppress tumorigenesis in rats subsequently \[[@B9],[@B10]\]. While Schinkel et al. conducted a study comparing normal *MDR1*a (+/+) mice (*MDR1*a is the mouse equivalent to the human *MDR1* gene) to constructed *MDR1*a (−/−) disrupted mice to find that the *MDR1*a (−/−)mice resulted in cumulative toxicity of the pesticide, ivermectin due to decreased extrusion of these compounds \[[@B11]\]. Considering these data, we can infer that genetical absence of Pg-p expression may result in more exposure to environmental xenobiotics so that increased opportunity linked to the risk of malignancy was obtained. However, the causal relationship between *MDR1* and the tumorigenesis has not been fully elucidated yet.

Recently, at least 50 single-nucleotide polymorphisms have been reported within *MDR1* gene locus \[[@B12],[@B13]\]. Among the systematic screens of this gene, Hoffmeyer et al. reported significant role that a synonymous SNP played at position 3435 located in exon 26 in the P-glycoprotein function \[[@B14]\]. Recent studies have found that C3435T was in linkage disequilibrium with two other common SNPs, the synonymous C1236T (exon 12) and nonsynonymous triallelic G2677T/A (exon 21) \[[@B15]-[@B17]\].

Considering the potential influence of these SNPs, many molecular epidemiological studies were conducted to investigate the association between these SNPs and cancer risk in humans. However, the results from different studies are to some extent divergent, but nevertheless intriguing, which may be owing to limitations in individual studies. To clarify this issue, we performed a meta-analysis with subgroup analysis from all eligible studies focusing on 3435C \> T, 1236C \> T and 2677G \> T/A, to obtain a more precise estimation of the relationship between polymorphisms and cancer risk.

Material and methods
====================

Identification and eligibility of relevant studies
--------------------------------------------------

All case--control studies on the association between *MDR1* polymorphisms and cancer risk published up to November 30, 2012 were identified through comprehensive searches using the PubMed and Medline database, ScienceDirect database, Springerlink database, Wiley Online Library, BioMed Central, Nature Series, Science Online, Cell Press Journals, CNKI, WanFang database with the following terms and keywords: "*MDR1*," "*ABCB1*," "single-nucleotide polymorphism," and in combination with "leukemia," "cancer," "tumor" and "carcinoma." The search was limited to human studies. In addition, we have especially reviewed the references cited in checked articles and identified some additional articles missed by the searching.

Inclusion criteria
------------------

The following criteria were used for the study selection: (1) a case--control study evaluating at least one of these three polymorphisms (3435C \> T, 1236C \> T and 2677G \> T/A) and cancer risk; (2) studies with full-text articles; (3) no overlapping data. and (4) sufficient data for estimating an odds ratio (OR) with 95% confidence interval (95% CI).

Data extraction
---------------

Information was carefully extracted from all the eligible publications. The following data were collected from each study: first author's name, publication date, country, ethnicity, cancer type, source of controls (population-based \[PB\] or hospital-based \[HB\] controls), genotyping method, total numbers of cases and controls and number of cases and controls for each *MDR1* polymorphism. Meanwhile, different case--control groups in one study were considered as independent studies. For each study, we did not define a minimum number of patients for inclusion in our meta-analysis.

Statistical methods
-------------------

The strength of association between *MDR1* polymorphisms and cancer risk was measured by ORs with 95% CIs. The risks (ORs) of cancer associated with the three

polymorphisms were estimated for each study. In our study, the C- allele, C-allele and G-allele were considered the reference genotypes, respectively in 3435C \> T, 1236C \> T and 2677G \> T/A. The pooled ORs were performed for co-dominant model (TT vs. CC and TC vs. CC, TT + TA + AA vs. GG and GT + GA vs. GG), dominant model (TC + TT vs. CC, TT + TA + AA + GT + GA vs. GG) and recessive model (TT vs. TC + CC, TT + TA + AA vs. GT + GA + AA), respectively. Heterogeneity assumption was checked by a *χ*2-based Q-test. A p-value of \>0.05 for the Q-test indicated a lack of heterogeneity among studies, so that the pooled OR estimate of each study was calculated by the fixed-effects model (the Mantel--Haenszel method). Otherwise, the random-effects model (the DerSimonian and Laird method) was used. Heterogeneity was quantified with the I^2^ metric, which is independent of the number of studies in the meta-analysis (I^2^ \< 25%: no heterogeneity; I^2^ = 25--50%: moderate heterogeneity; I^2^ = 50--75%: large heterogeneity, I^2^ \> 75%: extreme heterogeneity). Subgroup analyses were performed by cancer type (if one cancer type contained fewer than three individual studies, it was combined into an "other cancers" group), ethnicity and source of controls. Before analysis for each study, we examined whether the genotype distribution of controls was consistent with Hardy-- Weinberg equilibrium using the *χ*2 test. We performed One-way sensitivity analysis by deleting a single study in the meta-analysis each time to reflect the influence of the individual data set to the pooled OR to assess the stability of the results. An estimate of potential publication bias was carried out by the funnel plot, in which the standard error of log (OR) of each study was plotted against its log (OR). An asymmetric plot suggests a possible publication bias. Funnel plot asymmetry was assessed by the method of Egger's linear regression test, a linear regression approach to measure funnel plot asymmetry on the natural logarithm scale of the OR. The significance of the intercept was determined by the *t*-test suggested by Egger (p \< 0.05 was considered a significant publication bias). All of the statistical tests used in our meta-analysis were performed by SPSS version 13.0 and STATA version 11.0 (Stata, College Station, TX).

Results
=======

Eligible studies and meta-analysis databases
--------------------------------------------

A total of 48 publications with 52 case--control studies exploring the association between *MDR1* 3435C \> T, 1236C \> T and 2677G \> T/A polymorphisms and cancer risk were found \[[@B2],[@B5],[@B18]-[@B62]\]. Hence, as summarized in Table [1](#T1){ref-type="table"}, 52 studies (15789 cases and 20274 controls) for 3435C \> T polymorphism, 10 studies (2101 cases and 2842 controls) for 1236C \> T polymorphism and 18 studies (3585 cases and 4351 controls) for 2677G \> T/A polymorphism were selected in the meta-analysis, of which one publications had three independent studies and were considered separately. As summarized in Table [1](#T1){ref-type="table"}, there were 25 hospital-based studies and 26 population-based studies. There were 8 acute lymphoblastic leukemia (ALL) studies, 14 colorectal cancer studies, 9 breast cancer studies, 4 gastric cancer studies, 3 renal cell cancer studies, 2 acute myelocytic leukemia (AML) studies, 2 lung cancer study, 2 B-cell chronic lymphocytic leukemia (CLL) studies, one endometrial cancer study, one esophageal squamous cell carcinoma study, one glioma study, one upper aerodigestive tract (UADT) cancers study, one multiple myeloma study, one leukemia study, one plasma cell myeloma study and one study with Hodgkin's lymphoma (HL). Thirty-three studies were conducted in Europeans, seventeen studies were conducted in Asians. Two of the remained studies were conducted in Americans, and the other was in Mexicans. These studies indicate that the distribution of genotypes in controls was consistent with Hardy--Weinberg equilibrium. And the subjects of controls were matched for age and gender. Most of the cases were confirmed histologically or pathologically.

###### 

Characteristics of studies included in the meta-analysis

   **References**     **First author's name**     **Year of publication**             **Country of origin**                          **Cancer type**                **Ethnicity**            **SNPs**             **Source of control groups**        **Matching criteria**         **Genotyping methods**   **Case**   **control**       **MAF**          **HWE**
  ---------------- ----------------------------- ------------------------- -------------------------------------------- ------------------------------------------ --------------- ----------------------------- ------------------------------ ---------------------------------- ------------------------ ---------- ------------- ----------------- ----------------
         18                Rong-rong Liu                   2008                            Hunan, China                                    ALL                          Asian       C3435T,C1236T,G2677T,G2677A                HB                      Age, gender, weight                 PCR-RFLP             48          100       0.17;0.24;0.04    0.60;0.21;0.07
         19                 Zhi-zhuo Du                    2010                           Suzhou, China                                    ALL                          Asian         C3435T,C1236T,G2677T/A                   HB                          Age, gender                     SNP-shot            176          170       0.30;0.38;0.27    0.00;0.28;0.23
         2               Kevin Y. Urayama                  2007                Northern and Central California, USA                        ALL                                        C3435T,C1236T,G2677T/A                   HB                  Age, gender, Hispanic status            PCR-SBEP            294          369       0.25;0.21;0.18    0.30;0.13;0.18
         3               Hiroyoshi Hattori                 2007                               Japan                                        ALL                          Asian                 C3435T                           HB                          Age, gender                      Taqman             622          96             0.18              0.3
         20                 Jamroziak K                    2004                               Poland                                       ALL                        Caucasian               C3435T                           PB                          Age, gender,                    PCR-RELP            113          175            0.24               0
         21             Evelia Leal-Ugarte                 2008                               Mexico                                       ALL                                                C3435T                           PB                             Gender                       PCR-RELP            107          111            0.28              0.02
         22              A' gnes F. Semsei                 2008                              Hungary                                       ALL                        Caucasian           C3435T,G2677T/A                      PB                    Age, gender, risk group               PCR-RELP            378          189          0.29;0.28        0.07;0.13
         23               Vibeke Andersen                  2009                               Danish                                colorectal cancer                 Caucasian        C3435T,G-rs3789244-A                    PB                          Age, Gender,                     TaqMan             359          765            0.33              0.47
         24                Daniele Campa                   2012                           Czech Republic                            colorectal cancer                 Caucasian               C3435T                           HB                          Age, Gender,                     Taqman             699          622            0.29              0.79
         24                Daniele Campa                   2012                         Southwest Germany                           colorectal cancer                 Caucasian               C3435T                           HB                Age, Gender, county of residence           Taqman             1809        1853            0.28              0.91
         24                Daniele Campa                   2012                         Southwest Germany                           colorectal cancer                 Caucasian               C3435T                           PB                          Age, Gender,                     Taqman             2169        1634            0.29              0.62
         25               Urosˇ Potocnik                   2008                              Slovenia                            MSI-H colorectal cancer              Caucasian        C3435T,C1236T,G2677T                    HB                          Age, Gender,                     TaqMan              38          355       0.30;0.18;0.19    0.66;0.33;0.24
         26               Nizar M Mhaidat                  2011                               Jordan                                        HL                          Asian                 C3435T                           HB                              Age                         PCR-RFLP            130          120            0.35              0.11
         27                Sun-Young Bae                   2006                               Korea                                 colorectal cancer                   Asian                 C3435T                           HB                          Age, Gender,                    PCR-RFLP            111          93             0.16              0.01
         28                 Azam Khedri                    2011                                Iran                                 colorectal cancer                 Caucasian               C3435T                           HB                          Age, Gender,                    PCR-RFLP            118          137            0.35              0.56
         29              Mateusz Kurzawski                 2005                               Poland                                colorectal cancer                 Caucasian               C3435T                           HB                          Age, Gender,                    PCR-RFLP            184          188            0.29              0.27
         30                Chiko Komoto                    2006                               Japan                                 colorectal cancer                   Asian          C3435T,C1236T,G2677T                    HB                          Age, Gender,                     TaqMan              48          154       0.16;0.375;0.36   0.62;0.36;0.37
         30                Chiko Komoto                    2006                               Japan                         esophageal squamous cell carcinoma          Asian          C3435T,C1236T,G2677T                    HB                          Age, Gender,                     TaqMan              47          154       0.17;0.39;0.34    0.66;0.34;0.64
         31                  Bo-In Lee                     2006                               Korea                                 colorectal cancer                   Asian                 C3435T                           HB                          Age, Gender,                    PCR-RFLP             64          64             0.13              0.15
         32                Elena Osswald                   2006                               Russia                                colorectal cancer                 Caucasian           C3435T,G2677T/A                      HB                 Age, Gender, Smoking intensity           PCR-RFLP            285          275          0.26;0.20        0.35;0.42
         33               Mariusz Panczyk                  2009                               Poland                                colorectal cancer                 Caucasian        C3435T,C1236T,G2677T                    HB                          Age, Gender,                    PCR-RFLP             95          95        0.20;0.17;0.18    0.99;0.72;0.60
         34          Darinka Todorova Petrova              2008                              Bulgaria                               colorectal cancer                 Caucasian            C3435T,G2677T                       HB                          Age, Gender,                     RT-PCR             146          160          0.25;0.21        0.73;0.32
         35                   J Sainz                      2011                           South Germany                             colorectal cancer                 Caucasian               C3435T                           PB                          Age, Gender,                      PCR               1765        1784            0.27              0.6
         36                 Cizmarikova                    2010                          Eastern Slovakia                             breast cancer                   Caucasian               C3435T                           PB                          Age, Gender,                    PCR-RFLP            221          113            0.27              0.6
         37                  M. Taheri                     2010                                Iran                                   breast cancer                   Caucasian               C3435T                           HB                          Age, Gender,                    PCR-RFLP             54          50             0.26              0.61
         38                  Tatari F                      2009                         North east of Iran                            breast cancer                   Caucasian               C3435T                           HB                            Gender,                         PCR               106          77             0.29              0.59
         39                Joseph George                   2009                               India                                   breast cancer                     Asian                 C3435T                           HB                            Gender,                         PCR                86          68             0.15              0.7
         40             Henriquez-Hernandez                2009                               Spain                                   breast cancer                   Caucasian               C3435T                           HB                            Gender,                       PCR-RFLP            135          301            0.19              0.66
         41                  Nordgard                      2007                               Norway                                  breast cancer                   Caucasian       C3435T,C1236T,G2677T/A                  N.A.                         Age, Gender,                    PCR-RFLP            109          93        0.13;0.26;0.26    0.27;0.16;0.03
         42               Sebahat Turgut                   2007                               Turkey                                  breast cancer                   Caucasian               C3435T                           PB                            Gender,                       PCR-RFLP             57          50             0.24              0.62
         43                    Wu H                        2012                               China                                   breast cancer                     Asian         C3435T,C1236T,G2677T/A                   PB                          Age, Gender,                    PCR-RFLP            1173        1244       0.17;0.41;0.17    0.01;0.04;0.94
         44                  Z Sabahi                      2010                                Iran                                   Gastric cancer                  Caucasian               C3435T                           PB                          Age, Gender,                      PCR                48          131             0.3              0.58
         45             Mitsushige Sugimoto                2008                               Japan                                   Gastric cancer                    Asian                 C3435T                           HB                          Age, Gender,                    PCR-RFLP            150          168            0.17              0.68
         46              Tomomitsu Tahara                  2006                               Japan                                   Gastric cancer                    Asian                 C3435T                           HB                          Age, Gender,                    PCR-RFLP            157          104            0.21              0.64
         47              P.M. MROZIKIEWICZ                 2007                               Poland                                endometrial cancer                Caucasian               C3435T                           PB                          Age, Gender,                      PCR               198          488            0.26              0.61
         48             Federica Gemignani                 2007             six Central and Eastern European countries                 lung cancer                    Caucasian           C3435T,G2677T/A                      HB                          Age, Gender,                     TaqMan             299          317          0.24;0.21        0.62;0.01
         49                 S Haenisch                     2007                              Germany                                renal cell cancer                 Caucasian           C3435T,G2677T/A                      PB                          Age, Gender,                    PCR-RFLP             82          164          0.31;0.22        0.58;0.14
         50             Krzysztof Jamroziak                2006                               Poland                                       AML                        Caucasian               C3435T                           PB                          Age, Gender,                    PCR-RFLP            180          180            0.23              0.64
         51               Katie L. Miller                  2005                                USA                                        Glioma                      Caucasian               C3435T                           PB                          Age, Gender,                    PCR-RFLP            382          464            0.25              0.61
         52             Krzysztof Jamroziak                2006                               Poland                                    B-cell CLL                    Caucasian               C3435T                           PB                          Age, Gender,                    PCR-RFLP            110          201             0.2              0.65
         53              Michael Siegsmund                 2002                              Germany                     clear cell renal cell carcinoma (CCRCC)      Caucasian               C3435T                           PB                          Age, Gender,                    PCR-RFLP            179          150            0.29              0.59
         53              Michael Siegsmund                 2002                              Germany                                    non-CCRCC                     Caucasian               C3435T                           PB                          Age, Gender,                    PCR-RFLP             83          150             0.3              0.58
         54             Guillermo Gervasini                2006                               Spain                                    lung cancer                    Caucasian           C3435T,G2677T/A                      PB                          Age, Gender,                     TaqMan              96          86           0.26;0.31       0.61;0,。60
         55                Soya Sisy Sam                   2007                               India                      upper aerodigestive tract (UADT) cancers       Asian                 C3435T                           HB                          Age, Gender,                    PCR-RFLP            219          210            0.35              0.55
         56             Krzysztof Jamroziak                2008                               Poland                                 multiple myeloma                 Caucasian       C3435T,C1236T,G2677T/A                   PB                          Age, Gender,                    PCR-RFLP            111          96        0.19;0.15;0.18    0.66;0.01;0.55
         57                   V Rocha                      2008                               France                                     leukemia                     Caucasian               C3435T                           PB                          Age, Gender,                    PCR-RFLP            107          107             0.2              0.65
         58                STEPHEN DRAIN                   2009                                 UK                                 plasma cell myeloma                Caucasian               C3435T                           PB                          Age, Gender,                    PCR-RFLP             92          92             0.28              0.6
         59                  G. Penna                      2010                               Italy                                     B-cell CLL                    Caucasian            C3435T,G2677T                       PB                          Age, Gender,                    PCR-RFLP            125          125          0.25;0.30        0.62;0.00
         60         The MARIE-GENICA Consortium            2010                              Germany                                  breast cancer                   Caucasian               C3435T                           PB                          Age, Gender,                  MALDI-TOFMS           3148        5486            0.22              0.64
         61                 HYUN CHANG                     2009                               Korea                                   Gastric cancer                    Asian             C3435T,G2677T/A                      PB                          Age, Gender,                      PCR                43          118          0.34;0.23        0.56;0.21
         62               D Nageswara Rao                  2010                               India                                        AML                          Asian                 C3435T                           PB                          Age, Gender,                    PCR-RFLP            143          249            0.28              0.6
         62               D Nageswara Rao                  2010                               India                                        ALL                          Asian                 C3435T                           PB                          Age, Gender,                    PCR-RFLP            147          249            0.37              0.54

Abbreviations: *HB*: hospital-based; *PB*: population-based; *PCR-RFLP*: polymerase chain reaction-restriction fragment length polymorphism; *MAF*: minor allele frequency; *APEX*: arrayed primer extensions.

Quantitative synthesis
----------------------

There was a wide variation in the T-allele and T/A-allele frequency of 3435C \> T, 1236C \> T and 2677G \> T/A polymorphism between the two major ethnicities. For Asians, the T- allele frequency of 3435C \> T was 25.52% (95% CI =23.84--27.21%), which was significantly higher than that in Caucasians (24.28%, 95% CI = 20.54--28.03%, p \< 0.001). There was no statistical difference for the T- allele frequency of 1236C \> T between Asians (24.28%, 95% CI = 11.37--26.56%) and Caucasians (36.11%, 95% CI = 27.74--44.47%, p =0.633). And for Asians (23.47%, 95% CI = 19.78--25.96%) whose T/A-allele frequency of 2677G \> T/A polymorphism was not equivalent as Caucasians (22.87%, 95% CI = 11.12--35.82%, p =0.633).

Tables [2](#T2){ref-type="table"} summarizes the main results of the meta-analysis for *MDR1* 3435C \> T polymorphisms. Overall, we found that individuals with T-allele in 3435C \> T had a higher risk of cancer (co-dominant model TT versus CC: OR =1.286, 95% CI =1.123--1.474; CT versus CC: OR = 1.126, 95% CI = 1.020--1.244; dominant model TT + CT versus CC: OR = 1.176, 95% CI = 1.068--1.295; recessive model TT versus CT + CC: OR =1.191, 95% CI =1.065--1.333). In the subgroup analysis by cancer type, the results indicated that individuals with T-allele in 3435C \> T had significantly higher ALL risks (TT versus CC: OR =1.890, 95% CI =1.177--3.037), otherwise no significant association was found between higher CRC risks and T-allele in 3435C \> T, neither was between breast cancer and T-allele in 3435C \> T. When stratified by ethnicity, significantly elevated risks were observed among Caucasian populations(co-dominant model TT versus CC: OR =1.276, 95% CI =1.112--1.464; CT versus CC: OR = 1.172, 95% CI = 1.047--1.313; dominant model TT + CT versus CC: OR = 1.212, 95% CI = 1.083--1.357), whereas significantly elevated risks were not observed among Asian populations (co-dominant model TT versus CC: OR =1.314, 95% CI =0.894--1.933). When restricting the analysis to the source of controls, we found that HB genetic models had higher risks (TT versus CC: OR =1.307, 95% CI =1.046--1.632; dominant model: OR =1.170, 95% CI =1.009--1.357), and association was detected in PB genetic models also (TT versus CC: OR =1.294, 95% CI =1.079--1.552; CT versus CC: OR = 1.150, 95% CI = 1.019--1.299; dominant model TT + CT versus CC: OR = 1.459, 95% CI = 1.246--1.709; recessive model TT versus CT + CC: OR =1.183, 95% CI =1.033--1.355) (Figure [1](#F1){ref-type="fig"}).

###### 

**Stratified analysis of the*MDR1*3435C \> T polymorphism on cancer risk**

            **Genetic model**                                               **Homozygote**     **Heterozygote**   **Dominant model**    **Recessive model**                                                                                                                                                                         
  ------------------------------------- -------------------------------- -------------------- ------------------ --------------------- --------------------- ------------------------------- --------------------- --------------------- ------------------------------- --------------------- --------------------- -------------- ---------------------
                                         **Sample size (case/control)**    **OR (95% CI)**       **p**~**h**~     **I**^**2**^**(%)**     **OR (95% CI)**             **p**~**h**~            **I**^**2**^**(%)**     **OR (95% CI)**             **p**~**h**~            **I**^**2**^**(%)**     **OR (95% CI)**     **p**~**h**~   **I**^**2**^**(%)**
                                                                              TT vs. CC                                                      TC vs. CC                                                                TT + TC vs. CC                                                              TT vs. TC + CC                               
                 C3435T                         52(15789/20274)           1.286(1.123-1.474)        0.000               71.30%          1.126(1.020-1.244)                0.000                     58.20%          1.176(1.068-1.295)                0.000                     61.60%          1.191(1.065-1.333)       0.000             73.00%
              Cancer types                                                                                                                                                                                                                                                                                                          
    Acute lymphoblastic leukemia (ALL)            8(1381/1459)            1.890(1.177-3.037)        0.000               77.60%          0.981(0.683-1.410)                0.001                     70.10%          1.240(1.046-1.470)                0.153                     34.50%          1.829(1.095-3.054)       0.000             87.30%
            Colorectal cancer                    14(6362/7274)            1.047(0.875-1.254)        0.006               55.90%          1.053(0.906-1.224)                0.013                     51.80%          1.054(0.907-1.225)                0.005                     56.60%          1.014(0.939-1.094)       0.037             44.50%
              breast cancer                       9(5073/7498)            1.187(0.869-1.621)        0.001               69.30%          0.992(0.912-1.079)                0.190                     28.70%          1.098(0.906-1.331)                0.024                     54.80%          1.134(0.905-1.420)       0.017             57.10%
                Ethnicity                                                                                                                                                                                                                                                                                                           
                Caucasian                       33(12146/15989)           1.276(1.112-1.464)        0.000               60.40%          1.172(1.047-1.313)                0.000                      54.9%          1.212 (1.083-1.357)               0.000                      60.2%          1.062 (1.005-1.122)      0.001              47.7%
                  Asian                          17(2966/3418)            1.314(0.894-1.933)        0.000                80.4%          1.072(0.837-1.374)                0.000                      67.4%          1.153(0.915-1.453)                0.000                      67.9%          1.236(0.867-1.763)       0.000              84.4%
            Source of control                                                                                                                                                                                                                                                                                                       
                   HB                            25(5553/6173)            1.307(1.046-1.632)        0.000               69.10%          1.090(0.913-1.302)                0.000                     64.60%          1.170(1.009-1.357)                0.001                     54.90%          1.221(0.995-1.498)       0.000             76.80%
                   PB                           26(10143/13992)           1.294(1.079-1.552)        0.000               73.90%          1.150(1.019-1.299)                0.001                     53.20%          1.479(1.267-1.726)                0.000                     77.60%          1.183(1.033-1.355)       0.000             69.60%
                TT vs. CC                                                                         TC vs. CC                                                          TT + TC vs. CC                                                              TT vs. TC + CC                                                                     
                 C1236T                          10(2101/2842)            1.325(0.824-2.133)        0.000               77.10%          1.133(0.817-1.573)                0.005                     62.20%          1.173(0.825-1.668)                0.000                     70.60%          1.191(0.840-1.690)       0.000             77.80%
           TT + AA + TA vs. GG                                                                  TG + TA vs. GG                                                TT + AA + TA + TG + TA vs. GG                                               TT + AA + TA vs. TG + TA + GG                                                             
                G2677T/A                         18(3585/4351)            1.348(1.031-1.762)        0.000               68.70%          1.096(0.986-1.218)                0.136                     27.50%          1.161(1.051-1.281)                0.019                     45.50%          1.278(1.022-1.597)       0.000             68.00%
                Ethnicity                                                                                                                                                                                                                                                                                                           
                Caucasian                        11(1728/1950)            1.363(0.921-2.016)        0.000               73.60%          1.081(0.852-1.373)                0.029                     50.10%          1.149(0.899-1.467)                0.007                     58.80%          1.271(0.906-1.782)       0.000             74.60%
                  Asian                           6(1583/2040)            1.642(1.340-2.012)        0.142               39.50%          1.153(0.989-1.344)                0.804                      0.00%          1.273(1.101-1.471)                0.643                      0.00%          1.481(1.244-1.763)       0.192             32.50%
            Source of control                                                                                                                                                                                                                                                                                                       
                   HB                            10(1489/2220)            1.036(0.847-1.267)        0.045               47.80%          1.025(0.874-1.202)                0.072                     43.00%          1.032(0.888-1.198)                0.077                     42.10%          1.028(0.867-1.219)       0.137             33.90%
                   PB                             7(2005/2022)            1.641(1.018-2.646)        0.000               77.20%          1.164(1.008-1.345)                0.418                      0.70%          1.284(1.122-1.470)                0.099                     43.80%          1.537(0.998-2.366)       0.000             80.10%

*HB*: hospital-based; *PB*: population-based.

![**Forest plot of cancer risk associated with the*MDR1*3435C \> T polymorphism (TT vs. CC, random effects).** The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study-specific weight (inverse of the variance). The diamonds represent the pooled OR and 95% CI.](1475-2867-13-46-1){#F1}

We also found that T/A-allele frequency of 2677G \> T/A polymorphism was associated with higher risk of bearing cancer (2677G \> T/A: TT + TA + AA vs. GG: OR =1.348, 95% CI =1.031--1.762; dominant model: OR = 1.161, 95% CI = 1.051--1.281; recessive model: OR = 1.278, 95% CI =1.022--1.597). In the subgroup analysis by ethnicity, significantly elevated risks were observed among Asian populations (co-dominant model TT + TA + AA vs. GG: OR =1.642, 95% CI =1.340--2.012; dominant model: OR = 1.273, 95% CI = 1.101--1.471; recessive model: OR = 1.481, 95% CI = 1.244--1.763), however no significantly elevated risks were observed among Caucasian populations. When stratified by the source of controls, we couldn't find association between HB genetic models and higher cancer risks, but elevated risks could be associated with PB models (TT + TA + AA vs. GG: OR =1.641, 95% CI =1.018--2.646; GA + GT vs. GG: OR =1.164, 95% CI =1.008--1.345; dominant model: OR = 1.284, 95% CI =1.122--1.470).

The combined result based on all studies showed that there was no statistically significant link between cancer risk and 1236C \> T (1236C \> T: TT vs. CC: OR =1.325, 95% CI =0.824--2.133; CT vs. CC: OR = 1.133, 95% CI = 0.817--1.573; dominant model: OR = 1.173, 95% CI = 0.825--1.688; recessive model: OR = 1.191, 95% CI =0.840--1.690) (Table [2](#T2){ref-type="table"}).

Heterogeneity and sensitivity analyses
--------------------------------------

For 3435C \> T polymorphism, there was substantial heterogeneity among these studies for homozygote comparison (TT vs. CC: p heterogeneity = 0.000), and recessive model comparison (TT vs. CT + CC: p heterogeneity \< 0.001). Then, we assessed the source of heterogeneity for homozygote comparison (TT vs. CC) by ethnicity, cancer type and source of controls. We found that cancer type (*χ*2 = 18.51, df = 2 and p \< 0.001), ethnicity (*χ*2 = 9.58, df = 1 and p = 0.002) and the source of controls (*χ*2 = 4.42, df = 1 and p = 0.036) all contributed to substantial heterogeneity. Although the sample size for cases and controls in 52 studies ranged from 38 to 5,486, the corresponding pooled ORs were not qualitatively altered with or without the study of small sample. Similarly, no other single study influenced the pooled OR materially as indicated by sensitivity analysis.

And for 2677G \> T/A polymorphism, there was also heterogeneity for homozygote comparison (TT + TA + AA vs. GG: p heterogeneity = 0.000), recessive model comparison (p heterogeneity \< 0.001). The heterogeneity we decided to analyze was homozygote comparison (TT + TA + AA vs. GG). Due to cancer type (*χ*2 = 20.14, df = 7 and p = 0.005) and the source of controls (*χ*2 = 14.53, df = 1 and p \< 0.001), but not the ethnicity (*χ*2 = 1.28, df = 1 and p = 0.258).

Publication bias
----------------

We performed Begg's funnel plot and Egger's test to assess the publication bias of literatures. As shown in Figure [2](#F2){ref-type="fig"}, the shape of the funnel plots did not reveal any evidence of obvious asymmetry. The results of Egger's test still did not suggest any evidence of publication bias for 3435C \> T polymorphism (p =0.085 for TT vs. CC, p =0.273 for CT vs. CC, p = 0.102 for dominant model, respectively and p = 0.176 for recessive model). There are neither Publication bias for 1236C \> T polymorphism (p =0.247 for TT vs. CC, p =0.208 for CT vs. CC, p = 0.215 for dominant model, respectively and p = 0.332 for recessive model), nor for 2677G \> T/A polymorphism (p =0.716 for TT + TA + AA vs. GG and p = 0.656 for recessive model, p =0.841 for GT + GA vs. GG, p = 0.971 for dominant model, respectively).

![**Begg's funnel plots for publication bias test (3435C \> T TT vs. CC).** Each point represents a separate study for the indicated association. Log (OR), natural logarithm of OR. Horizontal line, means effect size.](1475-2867-13-46-2){#F2}

Discussion
==========

ATP-binding cassette (ABC) is one of the largest families of active importers and exporters that are located mainly in tissues acting as a barrier or having an excretory function. Most of the ABC transporters play a role in cell defense against environmental attacks generated by xenobiotics and intraceullar metabolic waste. The multidrug resistance 1 *(MDR1/ABCB1*) gene codes for P-glycoprotein, a membrane-bound transporter. Various cytokines, such as interleukin-1beta, benzo \[a\]pyrene and chemokines involved in inflammation seem to be the substrates of P-glycoprotein, which leading P-glycoprotein to be a potential cause of inflammation-induced carcinogenesis. *MDR1* also seems to play a role in preventing early apoptosis in tumor cells.

Significant *MDR1* gene heterogeneity, namely multiple mutations in the *ABCB1/MDR1* gene has been demonstrated in previous studies. Analysis of all 28 exons of the ABCB1/*MDR1* gene demonstrated at least 48 single-nucleotide polymorphisms (SNPs) to date, including promoter and the intron--exon region. The most frequent SNP *MDR1* 2677G \> T/A in exon 21 (RefSNP ID: rs2032582), leads to amino acid exchange from Ala to Ser or Thr. The silent mutation in exon 26 *MDR1* 3435C \> T (RefSNP ID: rs1045642) is associated with altered protein function. The third common polymorphism of *ABCB1/MDR1* gene is a silent mutation in exon 12 *MDR1* 1236C \> T (RefSNP ID: rs1128503). These three polymorphisms are closely related to linkage disequilibrium (LD). It was suggested that SNP is connected with susceptibility to many cancer types, such as renal epithelial tumors and acute lymphoblastic leukemia and CRC.

Our results showed that *MDR1* 3435C \> T polymorphism is associated with cancer risk when all studies were pooled together (TT versus CC: OR =1.286, 95% CI =1.123--1.474; CT versus CC: OR = 1.126, 95% CI = 1.020--1.244; dominant model TT + CT versus CC: OR = 1.176, 95% CI = 1.068--1.295; recessive model TT versus CT + CC: OR =1.191, 95% CI =1.065--1.333). In the stratified analysis by cancer type, the results indicated that individuals with T-allele in 3435C \> T had significantly higher ALL risks (TT versus CC: OR =1.890, 95% CI =1.177--3.037; TT + CT versus CC: OR = 1.240, 95% CI = 1.046--1.470; recessive model TT versus CT + CC: OR = 1.829, 95% CI =1.095--3.054), otherwise no significant association was found between higher CRC risks and T-allele in 3435C \> T, neither was between breast cancer and T-allele in 3435C \> T. When stratified by ethnicity, significantly elevated risks were observed among Caucasian populations(co-dominant model TT versus CC: OR =1.276, 95% CI =1.112--1.464; CT versus CC: OR = 1.172, 95% CI = 1.047--1.313; dominant model TT + CT versus CC: OR = 1.212, 95% CI = 1.083--1.357), whereas significantly elevated risks were not observed among Asian populations (co-dominant model TT versus CC: OR =1.314, 95% CI =0.894--1.933). When restricting the analysis to the source of controls, we found that HB genetic models had higher risks (TT versus CC: OR =1.307, 95% CI =1.046--1.632; dominant model: OR =1.170, 95% CI =1.009--1.357), and association was detected in PB genetic models also (TT versus CC: OR =1.294, 95% CI =1.079--1.552; CT versus CC: OR = 1.150, 95% CI = 1.019--1.299; dominant model TT + CT versus CC: OR = 1.459, 95% CI = 1.246--1.709; recessive model TT versus CT + CC: OR =1.183, 95% CI =1.033--1.355).

Inconsistent results might be attributed to the different roles *MDR1* played in different cell types or tissues. We've found the association between *MDR1* 3435C \> T polymorphism and ALL risk in subgroup analyses, as well as subgroup based on HB and PB genetic models. And in the stratified analysis by ethnicity, individuals carrying the T-allele in 3435C \> T were significantly associated with elevated cancer risk in Asian as well as Caucasian populations compared with C-allele carriers.

We also found that T/A-allele frequency of 2677G \> T/A polymorphism was associated with higher risk of cancer (2677G \> T/A: TT + TA + AA vs. GG: OR =1.348, 95% CI =1.031--1.762). In the subgroup analysis by ethnicity, significantly elevated risks were observed among Asian populations (co-dominant model TT + TA + AA vs. GG: OR =1.642, 95% CI =1.340--2.012), however no significantly elevated risks were observed among Caucasian populations. When stratified by the source of controls, we couldn't find association between HB genetic models and higher cancer risks, but elevated risks could be associated with PB models (TT + TA + AA vs. GG: OR =1.641, 95% CI =1.018--2.646; GA + GT vs. GG: OR =1.164, 95% CI =1.008--1.345; dominant model: OR = 1.284, 95% CI =1.122--1.470).

The combined result based on all studies showed that there was no statistically significant link between cancer risk and 1236C \> T (1236C \> T: TT vs. CC: OR =1.325, 95% CI =0.824--2.133; CT vs. CC: OR = 1.133, 95% CI = 0.817--1.573; dominant model: OR = 1.173, 95% CI = 0.825--1.688; recessive model: OR = 1.191, 95% CI =0.840--1.690).

It should be considered that the apparent inconsistency of these results may be caused by differences in disease prevalence, lifestyle, as well as possible limitations due to the relatively small sample size. The current knowledge of carcinogenesis indicates it is a process developed step by step, as well as influenced by multiple factors that involve various genetic alterations and several signaling pathways. Thus, it is unlikely that risk factors of cancer work in isolation from each other. Besides, even the same polymorphisms may act distinct roles in each cancer type, for different genetic backgrounds may contribute to the cancer discrepancy. And more importantly, the appearance determined by polymorphisms may largely depend on synthetically interaction with each polymorphism or a particular environmental exposure. Thus, it is possible that the effects of DNA repair function on cancer risk may be modified by multiple genetic polymorphisms. Also should we consider the chance findings as another plausible reason for the inconsistency of the results.

Although we have put considerable resources and efforts into discovering the association between *MDR1* polymorphism and cancer risk as possible as we can, there still exists some limitations. First, when stratified by the source of controls, our results indicated that studies using hospital-based controls rather than population-based controls had a significantly increased risk. The reason may be that the hospital-based studies have some biases because such controls may contain certain other diverse diseases which can cause different risks of developing into cancer of various organs and may not be so representative as the general population. Therefore, using proper and more representative cancer-free control subjects are crucial for reducing biases in such case--control studies. Second, our results were based on single-factor estimates without adjustment for other risk factors such as age, smoking and drinking status, environmental factors and other variables, which might have caused serious confounding bias. Third, some inevitable publication bias might exist. Finally, the number of the published studies was not sufficiently large for a comprehensive analysis, particularly for the 1236C \> T polymorphism. Hence we had to give up subgroup analysis for the polymorphism. For these limitations, our results should be interpreted with caution.

Our meta-analysis also has several strengths. First, statistically, a systematic review of the association of *MDR1* polymorphism between cancer risks is more powerful than any single study. Second, the quality of eligible studies included in current meta-analysis was satisfactory and met our inclusion criterion. Third, we did not detect sufficient publication bias indicating that the whole results might be unbiased.

In conclusion, our meta-analysis suggests that the *MDR1* 3435C \> T and 2677G \> T/A polymorphism may contribute to genetic susceptibility of cancers. And the results support that the minor T-allele of the *MDR1* 3435C \> T polymorphism is associated with a higher risk of acute lymphocytic leukemia, and significantly elevated risks were observed among Asian and Caucasian populations as well as HB and PB subgroups. And in the 2677G \> T/A polymorphism, those who carry the T-allele and A-allele were associated with higher cancer risks among Asians and PB subgroup. However, it is necessary to conduct large sample studies using standardized unbiased genotyping methods, homogeneous cancer patients and well-matched controls. Moreover, further studies estimating the effect of gene--gene and gene--environment interactions may eventually lead to our better, comprehensive understanding of the association between the *MDR1* polymorphism and cancer risk.
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